Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Ovarian Neoplasms × olaparib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 73 Observational 5 Expanded_access 1

Sponsor

Cancer Type

Conditions

PSR Ovarian Cancer With a BRCA Mutation 1 Ovarian Neoplasms 1 Ovarian Diseases 1 Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

ulixertinib 1 pegilodecakin 1 olaparib 1 niraparib 1 balstilimab 1 Proton Pump Inhibitors 1 Hydrocortisone 1 FANG vaccine 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡